Literature DB >> 21939358

Comparison of I-131 radioimmunotherapy tumor dosimetry: unit density sphere model versus patient-specific Monte Carlo calculations.

David M Howard1, Kimberlee J Kearfott, Scott J Wilderman, Yuni K Dewaraja.   

Abstract

High computational requirements restrict the use of Monte Carlo algorithms for dose estimation in a clinical setting, despite the fact that they are considered more accurate than traditional methods. The goal of this study was to compare mean tumor absorbed dose estimates using the unit density sphere model incorporated in OLINDA with previously reported dose estimates from Monte Carlo simulations using the dose planning method (DPMMC) particle transport algorithm. The dataset (57 tumors, 19 lymphoma patients who underwent SPECT/CT imaging during I-131 radioimmunotherapy) included tumors of varying size, shape, and contrast. OLINDA calculations were first carried out using the baseline tumor volume and residence time from SPECT/CT imaging during 6 days post-tracer and 8 days post-therapy. Next, the OLINDA calculation was split over multiple time periods and summed to get the total dose, which accounted for the changes in tumor size. Results from the second calculation were compared with results determined by coupling SPECT/CT images with DPM Monte Carlo algorithms. Results from the OLINDA calculation accounting for changes in tumor size were almost always higher (median 22%, range -1%-68%) than the results from OLINDA using the baseline tumor volume because of tumor shrinkage. There was good agreement (median -5%, range -13%-2%) between the OLINDA results and the self-dose component from Monte Carlo calculations, indicating that tumor shape effects are a minor source of error when using the sphere model. However, because the sphere model ignores cross-irradiation, the OLINDA calculation significantly underestimated (median 14%, range 2%-31%) the total tumor absorbed dose compared with Monte Carlo. These results show that when the quantity of interest is the mean tumor absorbed dose, the unit density sphere model is a practical alternative to Monte Carlo for some applications. For applications requiring higher accuracy, computer-intensive Monte Carlo calculation is needed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21939358      PMCID: PMC3189007          DOI: 10.1089/cbr.2011.0965

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  16 in total

1.  Re-evaluation of absorbed fractions for photons and electrons in spheres of various sizes.

Authors:  M G Stabin; M W Konijnenberg
Journal:  J Nucl Med       Date:  2000-01       Impact factor: 10.057

2.  Impact of nodal regression on radiation dose for lymphoma patients after radioimmunotherapy.

Authors:  Christine L Hartmann Siantar; Gerald L DeNardo; Sally J DeNardo
Journal:  J Nucl Med       Date:  2003-08       Impact factor: 10.057

3.  A radionuclide dosimetry toolkit based on material-specific Monte Carlo dose kernels.

Authors:  George Loudos; Ioannis Tsougos; Spyros Boukis; Nikolas Karakatsanis; Panagiotis Georgoulias; Kiki Theodorou; Konstantina Nikita; Constantin Kappas
Journal:  Nucl Med Commun       Date:  2009-07       Impact factor: 1.690

4.  MIRD pamphlet No. 17: the dosimetry of nonuniform activity distributions--radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee.

Authors:  W E Bolch; L G Bouchet; J S Robertson; B W Wessels; J A Siegel; R W Howell; A K Erdi; B Aydogan; S Costes; E E Watson; A B Brill; N D Charkes; D R Fisher; M T Hays; S R Thomas
Journal:  J Nucl Med       Date:  1999-01       Impact factor: 10.057

5.  OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine.

Authors:  Michael G Stabin; Richard B Sparks; Eric Crowe
Journal:  J Nucl Med       Date:  2005-06       Impact factor: 10.057

6.  131I-tositumomab therapy as initial treatment for follicular lymphoma.

Authors:  Mark S Kaminski; Melissa Tuck; Judith Estes; Arne Kolstad; Charles W Ross; Kenneth Zasadny; Denise Regan; Paul Kison; Susan Fisher; Stewart Kroll; Richard L Wahl
Journal:  N Engl J Med       Date:  2005-02-03       Impact factor: 91.245

7.  131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling.

Authors:  Yuni K Dewaraja; Matthew J Schipper; Peter L Roberson; Scott J Wilderman; Hanan Amro; Denise D Regan; Kenneth F Koral; Mark S Kaminski; Anca M Avram
Journal:  J Nucl Med       Date:  2010-06-16       Impact factor: 10.057

8.  Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.

Authors:  George Sgouros; Shannon Squeri; Ase M Ballangrud; Katherine S Kolbert; Jerrold B Teitcher; Katherine S Panageas; Ronald D Finn; Chaitanya R Divgi; Steven M Larson; Andrew D Zelenetz
Journal:  J Nucl Med       Date:  2003-02       Impact factor: 10.057

9.  Use of integrated SPECT/CT imaging for tumor dosimetry in I-131 radioimmunotherapy: a pilot patient study.

Authors:  Yuni K Dewaraja; Scott J Wilderman; Kenneth F Koral; Mark S Kaminski; Anca M Avram
Journal:  Cancer Biother Radiopharm       Date:  2009-08       Impact factor: 3.099

10.  Effect of patient morphology on dosimetric calculations for internal irradiation as assessed by comparisons of Monte Carlo versus conventional methodologies.

Authors:  Antigoni Divoli; Sophie Chiavassa; Ludovic Ferrer; Jacques Barbet; Glenn D Flux; Manuel Bardiès
Journal:  J Nucl Med       Date:  2009-01-21       Impact factor: 10.057

View more
  13 in total

1.  VIDA: a voxel-based dosimetry method for targeted radionuclide therapy using Geant4.

Authors:  Susan D Kost; Yuni K Dewaraja; Richard G Abramson; Michael G Stabin
Journal:  Cancer Biother Radiopharm       Date:  2015-01-16       Impact factor: 3.099

2.  Patient-Specific Dosimetry in Radioligand Therapy (RLT) for Metastatic Prostate Cancer Using 177Lu-DKFZ-PSMA-617.

Authors:  Elahe Mahmoudi; Elahe Pirayesh; Mohammad Reza Deevband; Mahasti Amoui; Mehrdad Ghorbani Rad; Mahdi Ghorbani
Journal:  Nucl Med Mol Imaging       Date:  2021-09-18

3.  Pretreatment CLR 124 Positron Emission Tomography Accurately Predicts CLR 131 Three-Dimensional Dosimetry in a Triple-Negative Breast Cancer Patient.

Authors:  Abigail E Besemer; Joseph J Grudzinski; Jamey P Weichert; Lance T Hall; Bryan P Bednarz
Journal:  Cancer Biother Radiopharm       Date:  2018-10-23       Impact factor: 3.099

4.  Development and Validation of RAPID: A Patient-Specific Monte Carlo Three-Dimensional Internal Dosimetry Platform.

Authors:  Abigail E Besemer; You Ming Yang; Joseph J Grudzinski; Lance T Hall; Bryan P Bednarz
Journal:  Cancer Biother Radiopharm       Date:  2018-04-25       Impact factor: 3.099

5.  MIRD pamphlet No. 24: Guidelines for quantitative 131I SPECT in dosimetry applications.

Authors:  Yuni K Dewaraja; Michael Ljungberg; Alan J Green; Pat B Zanzonico; Eric C Frey; Wesley E Bolch; A Bertrand Brill; Mark Dunphy; Darrell R Fisher; Roger W Howell; Ruby F Meredith; George Sgouros; Barry W Wessels
Journal:  J Nucl Med       Date:  2013-10-15       Impact factor: 10.057

6.  A dosimetric model for the heterogeneous delivery of radioactive nanoparticles In vivo: a feasibility study.

Authors:  Andrew B Satterlee; Peter Attayek; Bentley Midkiff; Leaf Huang
Journal:  Radiat Oncol       Date:  2017-03-17       Impact factor: 3.481

7.  Combined effects of Lenvatinib and iodine-131 on cell apoptosis in nasopharyngeal carcinoma through inducing endoplasmic reticulum stress.

Authors:  Guoyu Wang; Juhua Zhuang; Jing Ni; Ying Ye; Saifei He; Wei Xia
Journal:  Exp Ther Med       Date:  2018-08-23       Impact factor: 2.447

8.  Tumor necrosis factor-related apoptosis-inducing ligand additive with Iodine-131 of inhibits non-small cell lung cancer cells through promoting apoptosis.

Authors:  Ning Yang; Shuzhan Yao; Dong Liu
Journal:  Oncol Lett       Date:  2018-05-04       Impact factor: 2.967

9.  Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T.

Authors:  Julia Brosch-Lenz; Carlos Uribe; Astrid Gosewisch; Lena Kaiser; Andrei Todica; Harun Ilhan; Franz Josef Gildehaus; Peter Bartenstein; Arman Rahmim; Anna Celler; Sibylle Ziegler; Guido Böning
Journal:  EJNMMI Phys       Date:  2021-03-12

10.  Software-assisted dosimetry in peptide receptor radionuclide therapy with 177Lutetium-DOTATATE for various imaging scenarios.

Authors:  Dennis Kupitz; Christoph Wetz; Heiko Wissel; Florian Wedel; Ivayla Apostolova; Thekla Wallbaum; Jens Ricke; Holger Amthauer; Oliver S Grosser
Journal:  PLoS One       Date:  2017-11-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.